This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
By This Author:
Page 2 of 16

Biotech's Next Big Thing: Biogen

By Adam Feuerstein

Biogen Idec's earnings will be the next big thing in biotech says TheStreet Sr. Columnist Adam Feuerstein.

08:20AM 06/21/13

Biotech's Next Big Thing -- ASCO II

By Adam Feuerstein

TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.

02:09PM 05/16/13

Biotech's Next Big Thing: ASCO

By Adam Feuerstein

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.

09:39AM 05/09/13

Biotech's Next Big Thing: Aveo

By Adam Feuerstein

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

09:34AM 04/25/13

The Next Big Thing In Biotech: Titan

By Adam Feuerstein

Titan Pharmaceuticals is the next big thing in biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg

12:02PM 03/14/13

The Next Big Thing In Biotech: Onyx

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg why Onyx Pharmaceuticals is the next big thing in biotech.

01:11PM 03/07/13

The Next Big Thing In Biotech: DepoMed

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist at TheStreet, says DepoMed is the next big thing in biotech.

09:42AM 02/28/13

The Next Big Thing In Biotech: BIO CEO Conference

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.

11:38AM 02/07/13

The Next Big Thing In Biotech: Gilead

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says Gilead Sciences is the next big thing in biotech.

07:21AM 02/01/13

The Next Big Thing in Biotech: Celgene

By Adam Feuerstein

Senior columnist Adam Feuerstein says Celgene is the next big thing in biotech.

05:30AM 01/18/13

Page 2 of 16

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs